Nicholas Bello

Dr. Nicholas Bello

Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Cell
Verified
Journal Article
Closed access
ACAnutosh Chakraborty
Anutosh Chakraborty
MKMichael A. Koldobskiy
Michael A. Koldobskiy
NBNicholas Bello
Nicholas Bello
MMMicah Maxwell
Micah Maxwell
JPJames J. Potter
James J. Potter
SSSolomon H. Snyder
Solomon H. Snyder

1 January 2006 in Obesity
Verified
Journal Article
Open access
PDF file
VAVance L Albaugh
Vance L Albaugh
CHCathy R. Henry
Cathy R. Henry
NBNicholas Bello
Nicholas Bello
Andras HajnalAndras Hajnal
Andras Hajnal
SLSusan L. Lynch
Susan L. Lynch
CLChristopher J. Lynch
Christopher J. Lynch
Objective: To characterize a model of atypical antipsychotic drug‐induced obesity and evaluate its mechanism.Research Methods and Procedures: Chronically, olanzapine or clozapine was self‐administered via cookie dough to rodents (Sprague‐Dawley or Wistar rats; C57Bl/6J or A/J mice). Chronic studies measured food intake, body weight, adiponectin, active ghrelin, leptin, insulin, tissue wet weights, glucose, clinical chemistry endpoints, and brain dopaminergic D2 receptor density. Acute studies examined food intake, ghrelin, leptin, and glucose tolerance.Results: Olanzapine (1 to 8 mg/kg), but not clozapine, increased body weight in female rats only. Weight changes were detectable within 2 to 3 days and were associated with hyperphagia starting ∼24 hours after the first dose. Chronic administration (12 to 29 days) led to adiposity, hyperleptinemia, and mild insulin resistance; no lipid abnormalities or changes in D2 receptor density were observed. Topiramate, which has reversed weight gain from atypical antipsychotics in humans, attenuated weight gain in rats. Acutely, olanzapine, but not clozapine, lowered plasma glucose and leptin. Increases in glucose, insulin, and leptin following a glucose challenge were also blunted.Discussion: A model of olanzapine‐induced obesity was characterized which shares characteristics of patients with atypical antipsychotic drug‐induced obesity; these characteristics include hyperphagia, hyperleptinemia, insulin resistance, and weight gain attenuation by topiramate. This model may be a useful and inexpensive model of uncomplicated obesity amenable to rapid screening of weight loss drugs. Olanzapine‐induced weight gain may be secondary to hyperphagia associated with acute lowering of plasma glucose and leptin, as well as the inability to increase plasma glucose and leptin following a glucose challenge.

1 November 2010 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
NBNicholas Bello
Nicholas Bello
Andras HajnalAndras Hajnal
Andras Hajnal

1 August 2002 in NeuroReport
Verified
Journal Article
Closed access
NBNicholas Bello
Nicholas Bello
LLLouis R. Lucas
Louis R. Lucas
Andras HajnalAndras Hajnal
Andras Hajnal
A decrease in D2 dopamine receptor subtype (D2R) binding in the striatum has been reported in obese individuals and drug addicts. We examined D2R density in the striatum of food-restricted rats that had contingent access to food with different incentive values. Results showed that animals receiving limited access to 0.3 M sucrose paired 2 h with a chow meal for 7 days had a significantly lower D2R binding in nucleus accumbens shell and dorsolateral striatum compared with animals that had limited access to chow. There was no differential binding, however, in the accumbens core in any of the groups. These findings indicate that feeding conditions and sucrose intake influence D2R density specifically in subregions of the striatum.

14 December 2015 in Endocrinology
Verified
Journal Article
Open access
PDF file
JGJuliet D. Gotthardt
Juliet D. Gotthardt
JVJessica Verpeut
Jessica Verpeut
BYBryn L. Yeomans
Bryn L. Yeomans
JYJennifer A. Yang
Jennifer A. Yang
AYAli Yasrebi
Ali Yasrebi
NBNicholas Bello
Nicholas Bello
Clinical studies indicate alternate-day, intermittent fasting (IMF) protocols result in meaningful weight loss in obese individuals. To further understand the mechanisms sustaining weight loss by IMF, we investigated the metabolic and neural alterations of IMF in obese mice. Male C57/BL6 mice were fed a high-fat diet (HFD; 45% fat) ad libitum for 8 weeks to promote an obese phenotype. Mice were divided into four groups and either maintained on ad libitum HFD, received alternate-day access to HFD (IMF-HFD), and switched to ad libitum low-fat diet (LFD; 10% fat) or received IMF of LFD (IMF-LFD). After 4 weeks, IMF-HFD (∼13%) and IMF-LFD (∼18%) had significantly lower body weights than the HFD. Body fat was also lower (∼40%–52%) in all diet interventions. Lean mass was increased in the IMF-LFD (∼12%–13%) compared with the HFD and IMF-HFD groups. Oral glucose tolerance area under the curve was lower in the IMF-HFD (∼50%), whereas the insulin tolerance area under the curve was reduced in all diet interventions (∼22%–42%). HPLC measurements of hypothalamic tissue homogenates indicated higher (∼55%–60%) norepinephrine (NE) content in the anterior regions of the medial hypothalamus of IMF compared with the ad libitum-fed groups, whereas NE content was higher (∼19%–32%) in posterior regions in the IMF-LFD group only. Relative gene expression of Npy in the arcuate nucleus was increased (∼65%–75%) in IMF groups. Our novel findings indicate that intermittent fasting produces alterations in hypothalamic NE and neuropeptide Y, suggesting the counterregulatory processes of short-term weight loss are associated with an IMF dietary strategy.

1 August 2002 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
ACA. L. Curtis
A. L. Curtis
NBNicholas Bello
Nicholas Bello
KCK. R. Connolly
K. R. Connolly
RVR. J. Valentino
R. J. Valentino